Technical Analysis for ONCE - Spark Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
ONCE closed up 0.41 percent on Wednesday, January 17, 2018, on 68 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|See historical ONCE trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||Narrow Range Bar||Range Contraction||0.00%|
|Jan 17||NR7||Range Contraction||0.00%|
|Jan 17||Wide Bands||Range Expansion||0.00%|
|Jan 16||Multiple of Ten Bullish||Other||0.41%|
|Jan 16||Wide Bands||Range Expansion||0.41%|
|Jan 16||Gapped Down||Weakness||0.41%|
|Jan 12||Bearish Engulfing||Bearish||-2.15%|
|Jan 12||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-2.15%|
|Jan 12||Wide Bands||Range Expansion||-2.15%|
|Jan 11||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-4.70%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene. It is also developing SPK-CHM for the treatment of choroideremia; and preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases, as well as a pipeline of product candidates targeting rare blinding conditions. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B; and development and manufacturing collaboration with Genable Technologies Limited for the manufacture and provision of development advice in the development of Genable's therapeutic product candidate, GT038, to treat rhodopsin-linked autosomal dominant retinitis pigmentosa. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ONCE news...
|52 Week High||91.75|
|52 Week Low||41.06|
|200-Day Moving Average||67.1006|
|50-Day Moving Average||61.8294|
|20-Day Moving Average||51.72|
|10-Day Moving Average||52.276|
|Average True Range||3.1833|
|Chandelier Exit (Long, 3 ATRs )||47.0001|
|Chandelier Exit (Short, 3 ATRs )||54.3499|
|Upper Bollinger Band||55.3497|
|Lower Bollinger Band||48.0903|
|Percent B (%b)||0.47|
|MACD Signal Line||-3.3268|
|Market Cap||1.61 Billion|
|Num Shares||31.3 Million|
|Price-to-Earnings (P/E) Ratio||-8.06|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||53.77|
|Resistance 3 (R3)||53.79||53.07||53.39|
|Resistance 2 (R2)||53.07||52.50||53.06||53.27|
|Resistance 1 (R1)||52.30||52.15||51.94||52.28||53.14|
|Support 1 (S1)||50.81||51.01||50.45||50.79||49.92|
|Support 2 (S2)||50.09||50.66||50.08||49.79|
|Support 3 (S3)||49.32||50.09||49.67|
|Support 4 (S4)||49.30|